Head-to-head evidence
Iloperidone (PD psychosis use) vs Paliperidone palmitate (Invega Sustenna)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Iloperidone (PD psychosis use) · Fanapt
Marketed by Vanda Pharmaceuticals
NCT00254202 · Phase 3 · completed
The trial was randomized and quadruple-blind, included both placebo and active control groups, and enrolled 593 participants. Its primary clinical symptom endpoint was PANSS-T change, with mean changes of -12.0 for iloperidone versus -7.1 for placebo, but statistical significance of the comparison is not reported, so the result remains unclear.
Next expected readout: November 2027 · NCT06961968 (registry estimate)
Paliperidone palmitate (Invega Sustenna)
Marketed by Johnson & Johnson
NCT00101634 · Phase 3 · completed
The study was randomized and double-blind, with 518 participants and a placebo comparison, and used a clinical symptom measure (change in total PANSS score) as its primary endpoint. Because no results are posted, it is not possible to determine whether the primary endpoint was met.
Next expected readout: December 2026 · NCT07493551 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Iloperidone (PD psychosis use)'s landscape · Paliperidone palmitate (Invega Sustenna)'s landscape